Please login to the form below

Not currently logged in

Bind Therapeutics

This page shows the latest Bind Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Pfizer set to snap up Bind’s assets for $20m

Pfizer set to snap up Bind’s assets for $20m

Biotech approves 'stalking horse' bid from the pharma giant. Nano-engineering firm Bind Therapeutics has reached a $20m agreement with Pfizer for the purchase of the majority of its assets. ... Pfizer signed a $210m-plus nanomedicines deal with Bind in

Latest news

More from news
Approximately 3 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • Interview: AstraZeneca's Susan Galbraith Interview: AstraZeneca's Susan Galbraith

    Fostering partnerships. Recent developments include agreements to license the WEE1 inhibitor MK-1775 from Merck &Co and a collaboration with Bind Therapeutics which puts a molecule discovered by AZ – an Aurora

  • Deal Watch table for April 2013 Deal Watch table for April 2013

    Award. Smallpox vaccine research. 228. Bind Therapeutics/ Pfizer. Collaboration. Employ the Medicinal Nanoengineering platform to develop and commercialise Accurins. ... 200. Bind Therapeutics/ AstraZeneca. Collaboration. Employ the Medicinal

  • Pharma deals during April 2013 Pharma deals during April 2013

    Being bound to Bind– a popular choice. Bind Therapeutics did particularly well as a result of the frenzy, signing global deals with Pfizer and AstraZeneca (AZ), both based on Bind's ... carrying nanotech drug BIND-014, designed to selectively target

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

  • BIND Therapeutics appoints Andrew Hirsch as permanent CEO BIND Therapeutics appoints Andrew Hirsch as permanent CEO

    Nanomedicine company BIND Therapeutics has appointed Andrew Hirsch as president and chief executive, confirming him in the roles he has held on an interim basis since March. ... Before joining BIND Hirsch spent almost 10 years at Biogen, rising to VP of

More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

Happy Chinese New Year 2020 - The Year of The Rat
A fond farewell to The Year of the Pig...
White Paper for download - Explaining the price of your product
In this white paper, he breaks down the pricing options available to you, shares stories from his extensive experiences, and talks you through how to better define your pricing, step-by-step....
OPEN Health expands offering with the launch of a new Learning & Development specialist team
Enhanced expertise to deliver impactful internal training programmes for healthcare clients...